← Back to headlines
Neurocrine to Acquire Soleno for Drug Targeting Relentless Hunger Disorder
Neurocrine Biosciences announced its intent to acquire Soleno Therapeutics, a move that will secure a drug designed to treat a relentless hunger disorder, expanding Neurocrine's therapeutic portfolio.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
West Nile Fever Cases and Fatalities Reported in Serbia and North Macedonia
1h ago
Five Teenagers Die in Ireland Driving Wrong Way on Motorway for Social Media Trend
1h ago
Hayden Panettiere's Death at 36 Under Investigation
2h ago
Nikšić Children's Dispensary Undergoing Adaptation, Services Relocated
2h ago